basal insulin and glp 1 Beyond Insulin: How Glucagon-Like Peptide-1 Receptor Agonists Fit in the Spectrum of Therapeutic Options GLP-1-based therapies for type 2

5.3 SCFA production and anti-inflammatory effects Certain probiotic strains, particularly members of the Bifidobacterium and Lactobacillus genera, produce SCFAs, notably acetate, propionate, and butyrate, via the fermentation of dietary fibers (168)

Certain compounds in fenugreek, such as saponins , can support fat metabolism by stimulating specific enzymes that break down fat

Mona Gohara, M.D., board-certified dermatologist at Dermatology Physicians of Connecticut and member of the Prevention Medical Review Board

Market Size and Growth The market size for GLP-1 drugs (including diabetes and obesity indications) is already in the tens of billions of dollars annually

In db/db mice, CK treatment increases secondary BAs, such as lithocholic acid (LCA) and deoxycholic acid (DCA) through changes in the gut microbiota, especially the Ruminococcaceae family, and up-regulation of cytochrome P450 family 7 subfamily B member 1 ( Cyp7b1 ) and cytochrome P450 family 27 subfamily A member 1 ( Cyp27a1 ) and down-regulation of cytochrome P450 family 8 subfamily B member 1 ( Cyp8b1 ), which changes BA biosynthesis from the classical pathway to the alternative pathway

Similarly, semaglutide decreased plaque progression in LDLR-deficient mice by downregulating pro-inflammatory chemokines [24]